AJCN North Carolina Research Campus
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cynober, L. A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cynober, L. A
Agricola
Right arrow Articles by Cynober, L. A
American Journal of Clinical Nutrition, Vol. 76, No. 1, 255-256, July 2002
© 2002 American Society for Clinical Nutrition

Letter to the Editor

Clinical nutrition: commercially or clinically essential?

Luc A Cynober

Laboratoire de Biochimie A Hopital Hotel Dieu 1 Place du Parvis Notre Dame F-75181 Paris Cedex 04 France E-mail: luc.cynober{at}htd.ap-hop-paris.fr.Biol.

Dear Sir:

In a recent "Special Article" in the Journal, Buchman (1) has yet again (2) expressed his views on the use of glutamine-supplemented diets in clinical nutrition. However, I am concerned about his lack of objectivity in many of the examples proposed in his paper. For example, he 1) confuses the results of poorly designed studies with those of well-designed studies, 2) refutes the results of well-designed studies by emphasizing their minor methodologic weaknesses, 3) states that particular studies have flaws but does not substantiate these flaws, 4) combines the results of studies of the effects of enteral and parenteral nutrition even though the differences in glutamine's effects with the route of administration were emphasized in a remarkable analysis (3), 5) does not mention the results of some important studies that do not support his conclusions, and 6) says that the results of experimental studies should not be considered in the discussion of glutamine's effects; however, he cites such studies when it suits his purpose. From Buchman's review, it would have been just as easy to conclude that enteral nutrition has no advantage over parenteral nutrition, that parenteral nutrition is not efficacious in perioperative nutrition, that the usefulness of early enteral nutrition remains to be shown, or that fiber is not efficacious in enteral nutrition.

In particular, the author calls ornithine {alpha}-ketoglutarate a glutamine precursor (4). However, in an important paper published in this Journal coauthored by Buchman, ornithine {alpha}-ketoglutarate administration restored growth in infants receiving long-term total parenteral nutrition (5). Three different studies indicate that ornithine {alpha}-ketoglutarate improves wound healing in burn patients (6–8). One can argue that the effects of ornithine {alpha}-ketoglutarate are not mediated by glutamine. This is possible but not certain (9,10). In any case, the literature supporting this finding should have been considered by Buchman.

What does "commercially essential" in the title of Buchman's article mean? Available products are marketed by companies whose job it is to make money, which permits a reinvestment in research.

REFERENCES

  1. Buchman AL. Glutamine: commercially essential or conditionally essential? A critical appraisal of the human data. Am J Clin Nutr 2001;74:25–32.[Abstract/Free Full Text]
  2. Buchman AL. Glutamine: is it a conditionally required nutrient for the human gastrointestinal system? J Am Coll Nutr 1996;15:199–205.[Abstract]
  3. Alpers DH. Is glutamine a unique fuel for small intestinal cells? Curr Opin Gastroenterol 2000;16:155–9.
  4. Le Bricon T, Cynober L, Baracos VE. Ornithine {alpha}-ketoglutarate limits muscle protein breakdown without stimulating tumor growth in rats bearing Yoshida acites hepatoma. Metabolism 1994;43:899–905.[Medline]
  5. Moukarzel AA, Goulet O, Salas JS, et al. Growth retardation in children receiving long-term total parenteral nutrition: effects of ornithine {alpha}-ketoglutarate. Am J Clin Nutr 1994;60:408–13.[Abstract/Free Full Text]
  6. De Bandt JP, Coudray-Lucas C, Lioret N, et al. A randomized controlled trial of the influence of the mode of enteral ornithine alpha-ketoglutarate administration in burn patients. J Nutr 1998;128:563–9.[Abstract/Free Full Text]
  7. Donati L, Ziegler F, Pongelli G, Signorini MS. Nutritional and clinical efficacy of ornithine alpha-ketoglutarate in severe burn patients. Clin Nutr 1999;18:307–11.[Medline]
  8. Coudray-Lucas C, Le Bever H, Cynober L, De Bandt JP, Carsin H. Ornithine alpha-ketoglutarate improves wound healing in severe burn patients: a prospective randomized double-blind trial versus isonitrogenous controls. Crit Care Med 2000;28:1772–6.[Medline]
  9. Le Boucher J, Cynober L. Ornithine alpha-ketoglutarate: the puzzle. Nutrition 1998;14:870–3.[Medline]
  10. Le Boucher J, Farges MC, Minet R, Vasson MP, Cynober L. Modulation of immune response with ornithine alpha-ketoglutarate in burn injury: an arginine or glutamine dependency? Nutrition 1999;15:773–7.[Medline]




This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cynober, L. A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cynober, L. A
Agricola
Right arrow Articles by Cynober, L. A

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS